Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-04856883
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
PF-04856883 (also known as CVX-096) is a long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist developed by Pfizer using the proprietary CovX-Body platform. The molecule is a bioconjugate consisting of two GLP-1 mimetic peptides chemically linked to a humanized aldolase monoclonal antibody scaffold. This design utilizes the antibody's long circulating half-life to extend the bioactivity of the GLP-1 peptides, which are otherwise rapidly degraded by dipeptidyl peptidase-4 (DPP-4). PF-04856883 was evaluated in Phase 1 clinical trials for the treatment of type 2 diabetes mellitus, specifically in patients on metformin, but development was ultimately discontinued following Pfizer's decision to close the CovX research site.
- Other names
- CVX-096CVX096CVX 096GLP-1-CovX-BodyGLP1-CovX-BodyGLP 1-CovX-Body
02
Targets
Beyond the preview
Go deeper on PF-04856883.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-04856883.